Profile data is unavailable for this security.
About the company
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
- Revenue in USD (TTM)353.00k
- Net income in USD-50.39m
- Incorporated2005
- Employees56.00
- LocationaTyr Pharma Inc10240 Sorrento Valley Road, Suite 300SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 731-8389
- Fax+1 (858) 731-8394
- Websitehttps://www.atyrpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allakos Inc | 0.00 | -185.70m | 100.06m | 131.00 | -- | 0.5874 | -- | -- | -2.14 | -2.14 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -58.95 | -42.71 | -65.92 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| Inotiv Inc | 585.17m | -33.21m | 101.10m | 1.96k | -- | 0.3978 | 4.62 | 0.1728 | -1.29 | -1.29 | 22.73 | 9.85 | 0.6858 | 6.46 | 7.12 | 299,320.70 | -3.96 | -23.84 | -4.62 | -29.26 | 30.29 | 29.31 | -5.78 | -33.24 | 1.28 | 0.1431 | 0.5988 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Emergent Biosolutions Inc | 1.05bn | -760.50m | 101.11m | 1.60k | -- | 0.1552 | -- | 0.0964 | -14.75 | -14.75 | 20.43 | 12.44 | 0.4206 | 2.08 | 5.99 | 655,812.50 | -30.48 | -2.94 | -48.92 | -3.66 | 32.77 | 53.24 | -72.48 | -5.95 | 0.5383 | -1.96 | 0.5699 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Cellectar Biosciences Inc | 0.00 | -37.98m | 101.94m | 20.00 | -- | -- | -- | -- | -3.20 | -3.20 | 0.00 | -0.0654 | 0.00 | -- | -- | 0.00 | -225.65 | -83.69 | -499.83 | -99.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| IO Biotech Inc | 0.00 | -86.08m | 102.12m | 68.00 | -- | 0.7669 | -- | -- | -2.15 | -2.15 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -56.91 | -- | -62.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| OptiNose Inc | 70.99m | -35.48m | 102.31m | 132.00 | -- | -- | -- | 1.44 | -0.3162 | -0.3162 | 0.6329 | -0.7705 | 0.5635 | 0.9869 | 2.64 | 537,780.30 | -28.17 | -48.25 | -- | -98.95 | 87.84 | 86.96 | -49.99 | -131.66 | 0.5511 | -1.79 | 2.99 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Nanopharmaceutics Inc | 1.01m | -549.47k | 104.40m | 50.00 | -- | -- | -- | 103.41 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| GlycoMimetics Inc | 10.00k | -36.90m | 104.41m | 35.00 | -- | 2.72 | -- | 10,440.96 | -0.5841 | -0.5841 | 0.0002 | 0.5966 | 0.0002 | -- | 0.0625 | 285.71 | -75.98 | -43.60 | -90.65 | -47.82 | -- | -- | -368,994.20 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Abeona Therapeutics Inc | 3.50m | -54.19m | 106.96m | 84.00 | -- | 7.00 | -- | 30.56 | -2.59 | -2.59 | 0.1639 | 0.559 | 0.0546 | -- | 2.66 | 41,666.67 | -84.53 | -53.22 | -101.27 | -65.81 | -- | -- | -1,548.23 | -1,894.25 | -- | -- | 0.00 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| aTyr Pharma Inc | 353.00k | -50.39m | 108.03m | 56.00 | -- | 1.11 | -- | 306.02 | -0.9537 | -0.9537 | 0.0066 | 1.43 | 0.0033 | -- | 0.0497 | 6,303.57 | -46.57 | -45.45 | -54.04 | -52.74 | -- | -- | -14,276.77 | -784.19 | -- | -- | 0.0208 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Rezolute Inc | 0.00 | -56.83m | 110.75m | 51.00 | -- | 1.19 | -- | -- | -1.11 | -1.11 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -45.04 | -58.48 | -47.75 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| Relmada Therapeutics Inc | 0.00 | -98.79m | 111.34m | 20.00 | -- | 1.30 | -- | -- | -3.28 | -3.28 | 0.00 | 2.84 | 0.00 | -- | -- | 0.00 | -78.89 | -- | -87.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Sangamo Therapeutics Inc | 176.23m | -257.83m | 112.84m | 405.00 | -- | 1.17 | -- | 0.6403 | -1.46 | -1.46 | 1.01 | 0.4653 | 0.4843 | -- | 76.61 | 435,140.80 | -70.85 | -26.09 | -90.72 | -31.04 | -- | -- | -146.30 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Hongchang International Co Ltd | 2.68m | -378.79k | 115.49m | 8.00 | -- | 2.85 | -- | 43.16 | -0.0009 | -0.0009 | 0.0071 | 0.078 | 0.1065 | -- | 2.78 | -- | -1.51 | -7.98 | -1.60 | -10.94 | 2.59 | 11.47 | -14.16 | -64.88 | 3.74 | -- | 0.1417 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| FibroGen Inc | 147.75m | -284.23m | 116.39m | 486.00 | -- | -- | -- | 0.7877 | -2.93 | -2.93 | 1.52 | -2.07 | 0.2859 | 0.4597 | 6.28 | 304,016.50 | -55.51 | -30.62 | -119.42 | -42.31 | 87.24 | 93.52 | -194.16 | -119.08 | 1.33 | -53.30 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
Data as of May 02 2024. Currency figures normalised to aTyr Pharma Inc's reporting currency: US Dollar USD
55.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Federated Global Investment Management Corp.as of 31 Dec 2023 | 10.17m | 15.01% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 8.78m | 12.97% |
| Logos Global Management LPas of 31 Dec 2023 | 5.85m | 8.64% |
| Tikvah Management LLCas of 31 Dec 2023 | 2.46m | 3.63% |
| Alyeska Investment Group LPas of 31 Dec 2023 | 2.46m | 3.62% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.35m | 3.47% |
| Checkpoint Capital LPas of 31 Dec 2023 | 1.50m | 2.22% |
| Citadel Advisors LLCas of 31 Dec 2023 | 1.50m | 2.21% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.35m | 2.00% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 877.97k | 1.30% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
